Fluorescent dye imaging during breast cancer surgery
Part of Cancer, Skin clinical trials.
This trial tests a new imaging technique that uses a special dye and light to help surgeons see exactly where the tumor ends during breast cancer surgery, so they can remove the whole tumor while sparing healthy tissue. It may help reduce the chance of leaving cancer cells behind.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You are scheduled for surgery to remove a breast tumor.
- You have only one tumor, and it is either ≤5 cm (if you haven’t had chemotherapy before surgery) or cN0-1 (no or minimal lymph node involvement).
- No signs that the tumor has spread to your nipple, skin, chest wall, or distant parts of the body.
- You are not allergic to methylene blue or sodium fluorescein.
- You are able to understand the study and complete follow-up visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a fluorescent dye applied to tissue during surgery helps doctors see tumors and check if the tumor removal is complete. If you have a solid tumor and are scheduled for surgery, this study may improve the precision of your operation.
This trial tests a new imaging system that helps surgeons see if cancer cells remain after breast-conserving surgery. It may reduce the need for a second surgery by giving real-time feedback on the removed tissue.
This study uses a special camera to look at solid tumors from inside the body during an operation. It tests whether “live” tumor imaging (using a medicine called fluorescein) can be safely performed in people with certain solid cancers.
This study tests a new injectable dye (NC527-X) that helps surgeons see tumors better during surgery. The dye glows under special light, making it easier to find and remove cancer tissue completely.
This trial tests a special dye and imaging technique to help surgeons see and remove sarcoma tumors more completely. The goal is to reduce the chance that cancer cells are accidentally left behind during surgery.
This trial tests whether a special MRI and an injected light-activated dye (pHLIP® ICG) can help doctors see and target breast cancer during surgery. You may be offered this approach around the time of breast-conserving surgery, to improve how well the tumor area is identified.
Hear when a new Breast Cancer Early Stage Breast Cancer (Stage 1-3) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.